Full Press Release Details
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia.
LXRX
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
Key Takeaway: Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus